Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

FDA Approves 6-Month Formulation of Triptorelin Pamoate for Advanced Prostate Cancer NEW YORK -- March 11, 2010 -- The US Food and Drug Administration (FDA) has approved a new longer-acting, 6-month formulation of triptorelin pamoate for injectable suspension (Trelstar) for the palliative treatment of advanced prostate cancer. The approval is based on a 48-week, phase 3 study evaluating the efficacy, pharmacokinetics, and safety of triptorelin pamoate 22.5 mg administered every 6 months (24 weeks) in patients with advanced prostate cancer. Over the study, triptorelin pamoate produced a mean testosterone serum level of 12.8 ng/dL from month 2 through month 12, well below castration levels associated with androgen deprivation therapy. By day 29, 97.5% of the clinical trial patients achieved castrate level, and more than 98% of all patients were below castrate level at month 6 and month 12. Median prostate specific antigen (PSA) was also reduced by 96.4% at the end of the study. The most commonly reported adverse events included hot flushes (71.7%), erectile dysfunction (10.0%), and testicular atrophy (7.5%). SOURCE: Watson Pharmaceuticals, Inc. E-mail this page to a friend or colleague! To print, use this version